Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes
This is an extract from the guidance and may be misleading if read alone. The complete guidance is available at guidance.nice.org.uk/ta47
Important information about this guidance
This guidance has been partially updated by 'Unstable angina and NSTEMI' (NICE clinical guideline 94: www.nice.org.uk/guidance/cg94).
This guidance replaces 'Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes' (Technology Appraisal Guidance No 12) issued in September 2000.
The Institute reviews each piece of guidance it issues. The review and re-appraisal of the glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (ACS) has resulted in a revision of the definition of high-risk patients in relation to the use of these agents in initial medical management of ACS, and in a clarification of the recommendation on the use of a glycoprotein IIb/IIIa inhibitor as an adjunct to percutaneous coronary intervention.